You are viewing: South Korea Drug Discovery Technologies Market analysis

The South Korea Drug Discovery Technologies Market was valued at $233.6 Million in 2025 and projected to reach to $323.6 Million by 2030, representing a compound annual growth rate of CAGR 6.7%. South Korea's drug discovery technologies market is poised for steady growth through 2030, driven by continued government support for biotechnology infrastructure and a robust ecosystem of research institutions and pharmaceutical companies.

South Korea Drug Discovery Technologies Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

South Korea Drug Discovery Technologies Market Trends and Insights

  • South Korea has emerged as a significant hub for pharmaceutical innovation in the Asia Pacific region, driven by substantial government investment in biotechnology infrastructure and a highly skilled workforce.
  • The market in South Korea reflects strong demand for advanced computational tools, artificial intelligence-driven platforms, and high-throughput screening technologies that accelerate drug development timelines. The growth trajectory for South Korea's drug discovery technologies sector is supported by increasing collaboration between academic institutions, government research organizations, and private pharmaceutical companies.
  • South Korea's commitment to digital health and precision medicine initiatives is positioning the country as a competitive player in global drug discovery innovation.
  • Between 2025 and 2030, South Korea is expected to see heightened adoption of automation and AI-powered discovery platforms, driven by both domestic pharmaceutical firms and multinational companies establishing regional research centers..

Key Market Statistics

  • CAGR (2025-2030) CAGR 6.7%
  • Market Size, 2025 ~USD 233.6 Million
  • Forecast, 2030 ~USD 323.6 Million
  • Country South Korea

South Korea Drug Discovery Technologies Market Overview

Market Valuation Growth :

South Korea's drug discovery technologies market is valued at $233.6 million in 2025 and is projected to reach $323.6 million by 2030, demonstrating steady expansion in the regional pharmaceutical innovation sector.

Government-Backed Innovation :

South Korea benefits from substantial government investment in biotechnology infrastructure, positioning the country as a leading pharmaceutical innovation hub within the Asia Pacific region with competitive advantages in R&D capabilities.

Skilled Workforce Advantage :

The country maintains a highly skilled workforce specializing in drug discovery and biotechnology, supporting the development and adoption of advanced technologies across the pharmaceutical sector.

Regional Leadership :

South Korea has emerged as a significant hub for pharmaceutical innovation in Asia Pacific, attracting international partnerships and investments in drug discovery technology development and commercialization.

South Korea Drug Discovery Technologies Market Dynamics

  • The 6.7% CAGR reflects the country's strategic positioning as a regional innovation leader, with increasing adoption of advanced technologies such as AI-driven drug discovery, high-throughput screening, and computational biology platforms. The market outlook remains positive as South Korea strengthens its competitive position in global pharmaceutical innovation.
  • Ongoing investments in R&D facilities, talent development, and public-private partnerships are expected to accelerate market expansion.
  • The country's focus on precision medicine and personalized therapeutics will further drive demand for sophisticated drug discovery technologies, supporting sustained market growth and attracting international collaborations..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • South Korea's drug discovery technologies market is valued at $233.6 million in 2025 and will reach $323.6 million by 2030 at a 6.7% CAGR.
    • South Korea is leveraging government-backed biotechnology initiatives and academic-industry partnerships to accelerate drug discovery innovation.
    • AI and automation technologies are driving adoption in South Korea's pharmaceutical research sector, reducing time-to-market for new therapeutics.
    • South Korea's skilled workforce and digital health infrastructure position it as a regional leader in drug discovery technology adoption.

    Drug Discovery Technologies Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES (Technology)
    Forecast Period 2025–2030
    Growth Rate CAGR of 11% from 2025 to 2030
    Largest Segment REAGENTS & CONSUMABLES (Product)
    Market Size Base Year (Billions) ~USD 30.57 (2025)
    Revenue Forecast (Billions) ~USD 51.51 (2030)
    Segments Covered Product, Technology, Type, Process

    South Korea Drug Discovery Technologies Market Report Segmentation

    4 segment dimensions are covered across the global market.

    By Product

    • Bioinformatics Tools & Software
    • Instruments
    • Reagents & Consumables

    By Technology

    • Chromatography
    • High-Throughput Screening (Hts) Technologies
    • In-Silico/ AI-Based Drug Discovery Technologies
    • Mass Spectrometry
    • Next-Generation Sequencing
    • Other Technologies
    • Polymerase Chain Reaction
    • X-Ray Crystallography

    By Type

    • Automated Liquid Handling
    • Lab-On-A Chip
    • Label-Free Technology
    • Microplate-Based Hts

    By Process

    • Candidate Validation
    • Hit-To-Lead Identification
    • Lead Optimization
    • Target Identification
    • Target Validation

    Target Audience

    • Pharmaceutical Companies : South Korean and international pharma firms need this data to benchmark market position, identify growth opportunities, and make informed decisions about R&D investments and technology adoption in the region.
    • Biotech & Drug Discovery Firms : Emerging and established biotech companies require market insights to assess South Korea's attractiveness for expansion, understand competitive landscape, and evaluate partnerships with local research institutions.
    • Government & Policy Makers : South Korean government agencies and policy bodies use this market intelligence to evaluate biotechnology sector performance, justify continued investments, and develop strategic initiatives supporting pharmaceutical innovation.
    • Venture Capital & Investors : Investment firms and venture capitalists need South Korea-specific market data to identify promising drug discovery technology companies, assess market growth potential, and make capital allocation decisions.
    • Research Institutions & Universities : Academic and research organizations in South Korea require market insights to align research initiatives with commercial opportunities, secure funding, and establish partnerships with industry stakeholders.

    Key Companies in the South Korea Drug Discovery Technologies Market

    CompanyHQOwnershipStrongest segments
    THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
    MERCK KGAAGermanyPublic CompanyLife Science (tools, reagents, bioprocessing, CDMO),Healthcare (oncology, neurology, fertility, rare diseases),Electronics (semiconductor and display materials, gases, equipment),
    AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
    REVVITYUnited StatesPublic CompanyDiagnostics instruments and systems,Diagnostics reagents, assays, and kits,Life science reagents and consumables,
    ILLUMINA, INC.United StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep),Array-based instruments and consumables,
    DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology (bioprocessing and related solutions),Life Sciences (instruments, reagents, genomics, and imaging),Diagnostics (clinical instruments, consumables, software, services),
    BRUKERUnited StatesPublic CompanyBSI BioSpin (NMR/EPR and preclinical imaging),BSI CALID (mass spectrometry and diagnostics),BSI Nano (X-ray, AFM, EM analytics, optical microscopy),
    QIAGENNetherlandsPublic CompanySample technology consumables and instruments,Immune response and infectious disease diagnostics (incl. TB IGRA),Oncology and sexual & reproductive health assays,
    BIO-RAD LABORATORIES, INC.United StatesPublic CompanyClinical Diagnostics,Life Science Instruments and Systems,Life Science Reagents and Consumables,
    TAKARA BIO INC.JapanPrivate CompanyResearch reagents for genetic and cellular research,Instruments (PCR systems, cellular analysis devices),In vitro diagnostics (including COVID-19 testing),
    CORNING INCORPORATEDUnited StatesPublic CompanyOptical communications (fiber, cable, connectivity hardware),Display glass substrates (LCD and OLED),Specialty materials and optics,
    HAMILTON COMPANYUnited StatesPublic Investment FirmPrimary and secondary fund-of-funds,Direct credit and direct investments,Evergreen and customized solutions,
    PACBIOUnited StatesPublic CompanyLong-read instruments (Revio, Sequel, Vega),Long-read consumables and SMRT cells,Short-read Onso platform and consumables,

    THERMO FISHER SCIENTIFIC INC.

    Thermo Fisher Scientific Inc. is a leading United States-based life sciences company founded in 1956, employing 125,000 people globally. Operating as a public company, it provides a comprehensive portfolio of products and services for research, diagnostics, and bioproduction.

    MERCK KGAA

    Merck KGaA is a German multinational science and technology company with roots dating back to 1668, currently employing 59,077 people. As a public company, it operates across pharmaceuticals, life sciences, and performance materials sectors.

    AGILENT TECHNOLOGIES, INC.

    Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees. The company specializes in life sciences, diagnostics, and applied chemical markets with analytical instruments and services.

    REVVITY

    Revvity is a United States public company established in 1937, employing 11,000 people. It provides analytical and diagnostic solutions for life sciences, diagnostics, and applied markets.

    ILLUMINA, INC.

    Illumina, Inc. is a United States-based public company founded in 1998 with 8,625 employees. The company is a leader in DNA sequencing and genetic analysis technologies for research, diagnostics, and clinical applications.

    DANAHER CORPORATION

    Danaher Corporation is a diversified United States public company founded in 1969, employing 59,000 people worldwide. It operates across multiple segments including life sciences, diagnostics, environmental and applied solutions.

    BRUKER

    Bruker is a United States-based public company founded in 1960 with 11,085 employees. It manufactures scientific instruments for molecular and materials research, including mass spectrometry and NMR systems.

    QIAGEN

    QIAGEN is a Netherlands-based public company founded in 1984 with 5,500 employees. It specializes in sample and assay technologies for molecular diagnostics, applied testing, and life sciences research.

    BIO-RAD LABORATORIES, INC.

    Bio-Rad Laboratories, Inc. is a United States public company established in 1952 with 7,450 employees. It develops and manufactures clinical diagnostics and life science research products.

    TAKARA BIO INC.

    Takara Bio Inc. is a Japanese private company founded in 2002 with 1,779 employees. It develops and manufactures reagents and instruments for life science research and biotechnology applications.

    CORNING INCORPORATED

    Corning Incorporated is a United States public company with a history dating to 1851, employing 67,200 people. It operates across multiple industries including life sciences, with products for research, diagnostics, and bioproduction.

    HAMILTON COMPANY

    Hamilton Company is a United States-based public investment firm founded in 1991 with 785 employees. It provides laboratory automation and liquid handling solutions for life sciences and diagnostics.

    PACBIO

    PacBio is a United States public company founded in 2000 with 485 employees. It develops long-read DNA sequencing systems and services for genomics research and clinical applications.

    Reasons to Buy this Report

    • Market-Specific Sizing & Forecasts : Access precise valuation data for South Korea's drug discovery technologies market with detailed 2025-2030 projections, enabling accurate financial planning and investment decisions tailored to this specific regional market.
    • Regional Competitive Intelligence : Understand South Korea's unique position as an Asia Pacific pharmaceutical innovation leader, including government support mechanisms, infrastructure advantages, and competitive dynamics that differentiate this market from global trends.
    • Growth Driver Analysis : Identify key growth catalysts specific to South Korea including government biotechnology investments, workforce capabilities, and technology adoption patterns that inform strategic market entry and expansion strategies.
    • Investment & Partnership Opportunities : Discover targeted opportunities for partnerships, acquisitions, and investments within South Korea's drug discovery ecosystem, supported by detailed market insights and regional stakeholder analysis.
    • Regulatory & Operational Insights : Gain country-specific knowledge of South Korea's pharmaceutical regulatory environment, R&D infrastructure, and market dynamics essential for successful business operations and technology commercialization.

    Frequently asked questions

    What is the current market size of drug discovery technologies in South Korea?

    South Korea's drug discovery technologies market is valued at $233.6 million in 2025.

    What is the projected market size for South Korea by 2030?

    South Korea's drug discovery technologies market is projected to reach $323.6 million by 2030.

    What is the CAGR for South Korea's drug discovery technologies market?

    South Korea's drug discovery technologies market is expected to grow at a compound annual growth rate of 6.7% from 2025 to 2030.

    What are the key drivers of growth in South Korea's drug discovery market?

    Key drivers include government investment in biotechnology infrastructure, academic-industry collaborations, adoption of AI and automation technologies, and South Korea's commitment to precision medicine initiatives.

    Why is South Korea important in the Asia Pacific drug discovery market?

    South Korea has emerged as a significant regional hub due to its skilled workforce, advanced digital health infrastructure, government support for biotech innovation, and increasing multinational pharmaceutical presence.

    RESEARCH METHODOLOGY

    The research study involved the wide use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global drug discovery technologies market. Widespread interviews were conducted with various primary participants, including key industry members, subject-matter experts (SMEs), C-level managers of leading market players, and industry consultants, to obtain and verify qualitative and quantitative information and evaluate the growth scenarios of the market. The global market size is estimated through secondary research (top-down and bottom-up) followed by data triangulation with inputs from industry experts to arrive at the final market size.

    Secondary Research

    Secondary research was used mainly to identify and collect information for the technical, market-oriented, and commercial study of the drug discovery technologies market. The secondary sources used for this study include World Health Organization (WHO), Association of International Contract Research Organizations (AICROS), American Association of Pharmaceutical Scientists (AAPS), Eurostat, Clinical and Contract Research Association (CCRA), Association of Clinical Research Organizations (ACRO), Pharmaceutical Research and Manufacturers of America (PhRMA), India Brand Equity Foundation (IBEF), National Center for Biotechnology Information (NCBI), Food and Drug Administration (FDA). Academic Journals and Company Websites, corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations among others. These secondary sources were also used to obtain major information about key market players, and market segmentation corresponding to industry trends, regional/country-level markets, market developments, and technology prospects. Secondary data was collected and analysed to arrive at the market size of the global drug discovery technologies market, which was further validated through primary research.

    Primary Research

    Extensive primary research was conducted after acquiring basic knowledge about the global drug discovery technologies market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical & biopharmaceutical industries, academic institutes, and others from the supply side, such as C-level and D-level executives, product/ managers, marketing & sales managers of key manufacturers, distributors, and channel partners. The primary interviews were conducted across six major regions, including North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 60% and 40% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the drug discovery technologies market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    Drug Discovery Technologies Market

    Data Triangulation

    After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    Drug discovery is the process of developing a therapeutically active substance for a defined target molecule. Drug discovery is the early phase in which target identification, target validation, hit-to-lead identification, lead optimization, and candidate validation take place to deliver any suitable molecule or candidate for drug development. Drug discovery technologies are provided by contract research organizations (CROs) to pharmaceutical companies.

    Stakeholders

    • Drug discovery service providers
    • Pharmaceutical and biotechnology companies
    • Academic & Research Institutes
    • Contract Research Organization
    • Market Research and Consulting Firms
    • R&D Centers
    • Researchers and Scientists
    • Regulatory Agencies
    • Venture Capitalists
    • Government Organizations
    • Industry Associations and Professional Societies

    Report Objectives

    • To define, describe, and forecast the drug discovery technologies market by value by process, type, drug type, therapeutic area, end user and region
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall drug discovery technologies market
    • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six regions: North America, Europe, the Asia Pacific, Latin America, Middle East, and Africa
    • To profile the key players and analyze their market shares and core competencies2
    • To track and analyze competitive developments, such as product/service launches, partnerships, agreements, collaborations, and expansions
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

     

    Get the Full Drug Discovery Technologies Market Report

    Full forecast, segment splits, and company analysis for all Drug Discovery Technologies Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status